Previous 10 | Next 10 |
Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of Research-Use Only (RUO) target enrichment next-generation sequencing (NGS) panels for viral detection and characterization of samples from patients testing positive for SARS-CoV-2, the virus which causes COVID-19....
-- Positive Controls can be Used as Reference to Verify and Validate RT-PCR and NGS Assays -- Twist Bioscience Corporation (Nasdaq: TWST) today announced the availability of two synthetic SARS-CoV-2 RNA Controls. Positive controls provide quality control measures for the development, ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with SOPHiA GENETICS, leader in Data-Driven Medicine to bring access to the universal SOPHiA Plat...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, wi...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration to bring its target enrichment and sample library preparation kits to a novel automation platform...
-- Twist Comprehensive Exome Offers Maximum Sequence Efficiency with Best Coverage Uniformity to Increase Confidence in Gene Variant Detection -- -- Previews of Twist Targeted Methylation Solution to Investigate Differentially Methylated Regions for Epigenetic and Oncology Research ...
The OEM partnership will enable GenapSys customers turn-key access to Twist’s best-in-class target enrichment workflows, providing researchers with optimized assays spanning cancer test panels to whole human exome sequencing GenapSys Inc., the company behind the world’s ...
Shares of Twist Bioscience (NASDAQ: TWST) rose nearly 15% today after the company announced the pricing of a public offering of common stock. The DNA synthesis pioneer will issue up to 5.3 million shares at $28 apiece. The offering could bring in gross proceeds of up to $150 million. ...
Twist Bioscience (NASDAQ: TWST ) prices its public offering of ~4.6M common shares at $28.00 per share. Underwriters' over-allotment is an additional ~696K shares. Gross proceeds should be ~$130M (from $100M). More news on: Twist Bioscience Corporation, Healthcare stocks news, Stocks on ...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 4,642,857 shares of its common stock at a price to the public o...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...